Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
about
Alemtuzumab in chronic lymphocytic leukemiaSevere and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.Alemtuzumab in clinical practice: a British Columbia experience.Alemtuzumab for B-cell chronic lymphocytic leukemia.Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.The evolving role of alemtuzumab in management of patients with CLL.Monoclonal antibodies in chronic lymphocytic leukemia.Alemtuzumab in CLL and other lymphoid neoplasms.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational useAlemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).Antibody-based therapy of leukaemia.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review.Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.Viral infections and their management in patients with chronic lymphocytic leukemia.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Advanced heart failure due to cancer therapy.Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemiaProgressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.A case of severe drug reaction secondary to alemtuzumab with successful re-exposure.Alemtuzumab and chronic plaque psoriasis.Alemtuzumab in chronic lymphocytic leukemia.Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
P2860
Q33288974-57B5ED92-05FD-4A1F-AA1A-2EA41C17E133Q33366969-A12EF98A-08B4-4497-9880-6E989FC6DA2CQ33378464-E1281F7F-1C9D-486C-9B01-1CB4C1816609Q33380135-1DB51275-C140-47F3-AE7A-8F9F4C1A965DQ33395286-4318E26A-3B52-4B6F-9000-E1117CA1A6B9Q35382716-71396EBA-F3FA-4A16-A8CD-E7599F79CCA5Q36026719-85B93350-5331-496F-806F-F081D8B111EEQ36292883-08B8FFD2-074C-4178-B8B1-4D48D2FA8608Q36613987-38EBFFCA-A4D8-477A-81C4-7E061C53CF34Q36659824-A2C5719C-7F5E-4057-BAB7-198F2824B8A7Q36768605-76160291-1FF8-4C34-BA48-91403A3546A0Q36832113-01B5404E-A8E9-4096-922B-3DDB23FF9DE3Q36985872-20AB2064-A820-479A-AD41-FBDDCBA497B8Q37134417-761C3EF9-877F-4AFB-A96A-F99FE958AE39Q37307583-ECE12B2E-C7BB-458A-B3FD-903A31917E85Q37605247-0101B4AD-A12E-4FB9-A234-1B9909836D2AQ37767703-472B5D27-79D8-4646-9E4A-7C3095B8FD73Q37859378-B50CF462-CD69-4BA6-84D2-A50F5BD4F757Q38007853-FA6BE6C1-CB6C-4EE0-82CF-83D1C1108622Q38064527-3D5335C7-94CA-4468-BD07-247D52A0C5B2Q38331701-DF59FDC1-44B4-47DF-A738-A51E89B38E3FQ38357704-0FDA832C-1EB2-4179-8D61-46D2AA714C41Q38406251-DB58D9A7-CA26-486D-A2FF-62003A1B4CA8Q39532967-C31B6760-5D8E-47B0-8976-483F87C2F074Q40130220-A00D6D8F-1F91-439D-AFC0-5AC2C87FB8CEQ40293844-016E20B8-2CA4-485C-9338-0F76D11AC22CQ40476622-7A8F257E-A795-4EE7-9CFF-073331767456Q41693758-15105110-DC96-4B4F-A92C-6E8C41185E0FQ41924854-A05235EA-3E73-45BE-AA8B-E50A000873D4Q42149544-FDBCFA16-4213-4A9C-A0FB-3216D00AC4A3Q43477578-3D3FFFA7-64D6-4119-8408-DE01F7165181Q46817686-45AAE64B-CD8D-4746-A162-4C4725263383Q49902039-373F820E-9B4C-47A7-9F3A-8905DC131EE7Q50852822-957D3D2B-13C1-4C39-B47E-B56B9F8D1F79Q53572903-371E254E-5FEC-4FED-8FBC-A514FDAB9FB8Q57053368-7523147B-A9D3-4D79-8649-D65DADBC2295
P2860
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@ast
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@en
type
label
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@ast
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@en
prefLabel
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@ast
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@en
P2093
P50
P356
P1433
P1476
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
@en
P2093
Deborah A Thomas
Dimitrios P Kontoyiannis
Francis J Giles
Susan M O'Brien
P304
P356
10.1002/CNCR.11551
P407
P50
P577
2003-08-01T00:00:00Z